Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED).
| Author | |
|---|---|
| Abstract | :
In 2015, Vyvanse (lisdexamfetamine) became the first Food and Drug Administration (FDA)-approved treatment for binge-eating disorder (BED), a condition first recognized by the DSM-V in 2013. Because pharmaceutical companies use continuing medical education (CME) to help sell drugs, we explored possible bias in CME modules on BED. |
| Year of Publication | :
1969
|
| Journal | :
Journal of the American Board of Family Medicine : JABFM
|
| Volume | :
33
|
| Issue | :
2
|
| Number of Pages | :
240-251
|
| Date Published | :
1969
|
| ISSN Number | :
1557-2625
|
| URL | :
http://www.jabfm.org/cgi/pmidlookup?view=long&pmid=32179607
|
| DOI | :
10.3122/jabfm.2020.02.190129
|
| Short Title | :
J Am Board Fam Med
|
| Download citation |